SCHEMBL10201757

SCHEMBL10201757

CCC(=O)N1C[C@H](N)C(=O)N(CC(=O)OCc2ccccc2)c2ccccc21

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CCKBR P32239 2/20 0.39
CYP3A4 P08684 3/20 0.37
XIAP P98170 3/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
MAPK1 P28482 2/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ACE P12821 2/20 0.36
ABCB11 O95342 1/20 0.36
AGTR2 P50052 1/20 0.36
PDE3A Q14432 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CCKAR P32238 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10249419 0.86 LMNA (0.41) ALDH1A1
SCHEMBL10201707 0.86 LMNA (0.41) ALDH1A1
SCHEMBL13140306 0.85 XIAP (0.37) NOTUMCCKBRCYP3A4XIAP
SCHEMBL10201760 0.81 CYP3A4 (0.40) CCKBRCYP3A4XIAPACEABCB11
Hydrochloric Acid SCHEMBL646346 0.78 FAAH (0.47) CYP3A4XIAP
SCHEMBL10201755 0.77 XIAP (0.43) CYP3A4XIAP
SCHEMBL648053 0.76 LMNA (0.41) ALDH1A1
SCHEMBL10284665 0.76 LMNA (0.41) ALDH1A1
SCHEMBL7431122 0.76 ACE (0.50) NOTUMCYP3A4NPC1RAB9AL3MBTL1
SCHEMBL5712903 0.75 MME (0.48) NPSR1CCKBRNPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-28 US disclosed
US-8119631-B2 Inhibitors of interleukin-1β converting enzyme VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-21 US disclosed
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178069-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B NOTUM 1340/4885NPSR1 4495/4885CCKBR 3516/4885
US-20120165319-A1 INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME IL1A, IFNAR1, IL1B NOTUM 1340/4885NPSR1 4495/4885CCKBR 3516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.